From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bonus Bearcast: a short email from 'arry Adams and a long chat with Steve O'Hara

By Tom Winnifrith | Tuesday 3 December 2024


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


The email from Adams is interesting but many of you will not believe it but it's why selling shares in Kefi Gold & Copper (KEFI) today is an error. the long chat with O'Hara was needed to clarify today's RNS which is just not clear. I hope I clarify and cover a number of other matters relating to Optibiotix (OPTI), Probiotix (PBX) and SkinBiotherapetics (SBTX) shares in all three of which are, I believe, a STRONG BUY. I hope the podcast explains why.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 21:11:42